mk2 Biotechnologies

mk2 Biotechnologies receives a multi-million sum in seed funding.

The Munich-based startup wants to industrialize its new peptide production platform.

Munich, 29.06.2021: Several million Euros seed funding financing round was led by OCCIDENT, with the support of SeedBlink and primeCROWD. 


"mk2 Biotechnologies objective is to apply our unique platform approach for the synthesis and purification of authentic peptides at large scales, which can be broadly applied in several market segments. Using our synthesis technology, we can exceed both the customer quality and cost requirements. The key to our process is, that we were able to eliminate the existing bottlenecks of established technologies" said Dr. Sebastian Mangold, Managing Director and one of the three co-founders of mk2 Biotechnologies. 


"The funding committed by this experienced syndicate represents further validation of our technology and reflects the recent bioactive market development. The funding will enable us to continuously improve our platform and ramp up our production in order to move our first product candidates towards the application in volume markets such as cosmetics, food & beverages, agriculture, and pharmaceuticals"


mk2 Biotechnologies will transfer its R&D facilities this fall to the Innovation and Start-Up Center for Biotechnology in Martinsried (IZB), just outside of Munich, which will enable the targeted team, infrastructure, and business growth. "We are very much looking forward to our new facilities and the neighboring companies mainly active in the pharmaceuticals industry. We expect to leverage respective synergies and accelerate not only our industrially applicable product candidates but particularly our peptide-based APIs which are already in the development pipeline"  complemented Dr. Sebastian Mangold. 


Cèdric Barra, Senior Investment Manager at OCCIDENT, commented: "We see a lot of potential in the application of high-quality peptides. With the technology platform and the know-how that the team at mk2 brings with them, the company is in an excellent position for further development. We are very much looking forward to working with this motivated team in the future."


Dr. Ronald Rapberger, Chief Investment Officer of primeCROWD, added: "Being a molecular bologist myself, I'm confident in the ability of this outstanding team to bring the technology from the lab to the mass markets. This will finally make peptides available for currently underserved application areas and at competitive prices."


Peptides, which are short amino acid chains, can have extraordinary properties and modes of action. This substance class has been identified to be very promising for highly attractive applications in the areas of personal care, food & beverages (e.g. flavors, nutrition, and conservation), animal breeding (e.g. antibiotics substitutes), and crop cultivation (e.g. fungicide and fertilizer substitutes). However, established production methods are very costly and not scalable. Due to the enormously high prices, despite their often outstanding properties and the broad interest of the industry, peptides have so far not been applicable in products on the mass market. mk2 Biotechnologies precisely addresses this problem via a proprietary process that allows the scalable and thus cost-efficient production of high-purity peptides for arbitrary applications. Therefore, mk2 Biotechnologies provides the yet missing tool for the application of peptides in mass markets. 

 


mk2 Biotechnologies GmbH develops, produces, and investigates peptides at highest purity and quality standards using a revolutionary scalable synthesis technology. This way mk2 Biotechnologies enables the production of authentic peptides, regardless of their physical or chemical properties, at large scales and at low costs. 

OCCIDENT is an international venture capital investor with offices in Munich and Zug, is owner-managed, and invests own wealth. Its aim is to make positive contributions to society through sustainable and meaningful investments. 

OCCIDENT invests in innovative deep tech startups with excellent technologies in the fields of life sciences, high-tech, and digital with broad application possibilities and the potential for further value-generating developments. The geographic focus is in Germany and Switzerland. The preferred stage for initial financing is from seed rounds or later and from 0.5 million euros. OCCIDENT distinguishes itself in particular by its in-depth knowledge of the technology and the versatile support offered to its portfolio companies by its competent team of experts. https://www.occident.group/

 

SeedBlink is the fastest growing investing platform specialized in sourcing, vetting, financing, and scaling in European tech startups. The company aims to simplify the investment process for retail and accredited investors by combining crowd reach, business angel flexibility, and Venture Capital expertise, all in one internet platform. SeedBlink's booming investors community and the selection of startups are at the core of the platforms' success, along with optimized portfolio diversification through thesis-aligned matching and engagement tools. https://seedblink.com/

 

primeCROWD is one of the largest startup investor networks in the DACH region and includes more than 2,500 investors as well as numerous incubators, accelerators, and VCs.

primeCROWD acts as an interface between investors and startups with a focus on early-stage and growth financing in the technology, healthcare, digital economy, and sustainability sectors. Its declared goal is to accompany startups throughout the entire investment process.

Since its foundation in 2015, investments in 28 startups and in the amount of more than EUR 20 million have been realized (2 exits).